MIPS Project Detail:
Company
Company Description:
VLP Therapeutics is dedicated to developing innovative medical treatments and transforming traditional vaccines and targeted antibody therapies to address global unmet medical needs. Its vision is to combat 21st century global public health problems through its i-αVLP (inserted alpha VLP) Technology.
MIPS Project
VLPM01 malaria vaccine development
Project #
5712.21
|
MIPS Round
61
|
Starting Date:
Feb 2018
MIPS Project Challenge:
The goal of this MIPS project was to assist with the clinical study design for VLP Thereapeutics’ malaria vaccine, VLPM01, including regulatory documentation, protocol and an investigator’s brochure.
Project Scope:
Through this MIPS project, Laurens was slated to develop and finalize the protocol for the Phase I/IIa study of the company’s malaria vaccine, VLPM01. He planned to provide input on the overall design and help write the objectives, methodology, and clinical evaluation sections of the protocol. Laurens also assisted with the development and finalization of the Investigator’s Brochure, a comprehensive compilation of clinical and non-clinical data about the investigational product under study. Lastly, Laurens would serve as the medical monitor throughout the duration of the clinical study.
Results:
Through MIPS, Laurens continues to provide valuable clinical/regulatory input to the company’s upcoming malaria Phase 1/2a study and to help VLP Therapeutics meet its objectives in vaccine development.
Principal Investigator:
Matthew
Laurens
Associate Professor of Pediatrics and of Medicine, Center for Vaccine Development
Project Manager:
George
Moonsammy
Director of Clinical Development
Technologies:
Other
